UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors

The American journal of gastroenterology, 2006-04, Vol.101 (4), p.701-710

2006

Volltextzugriff (PDF)

NSAID-associated adverse effects and acid control aids to prevent them : A review of current treatment options

Drug safety, 2006-01, Vol.29 (2), p.119-132

2006

Volltextzugriff (PDF)

Low-Dose Aspirin Therapy for Cardiovascular Prevention: Quantification and Consequences of Poor Compliance or Discontinuation

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010-01, Vol.10 (2), p.125-141

2010

Volltextzugriff (PDF)

Randomized, Double-Blind, Placebo-Controlled Trial of the 5-HT1A Receptor Antagonist AZD7371 Tartrate Monohydrate (Robalzotan Tartrate Monohydrate) in Patients With Irritable Bowel Syndrome

The American journal of gastroenterology, 2008-10, Vol.103 (10), p.2562-2569

2008

Volltextzugriff (PDF)

Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs

Current medical research and opinion, 2009-11, Vol.25 (11), p.2785-2793

2009

Volltextzugriff (PDF)

Improvements with Esomeprazole in Patients with Upper Gastrointestinal Symptoms Taking Non-Steroidal Antiinflammatory Drugs, Including Selective COX-2 Inhibitors

The American journal of gastroenterology, 2005-05, Vol.100 (5), p.1028-1036

2005

Volltextzugriff (PDF)

Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic Acid: A Quantitative Study in Patients with Cardiovascular Risk

The patient : patient-centered outcomes research, 2011, Vol.4 (2), p.103-113

2011

Volltextzugriff (PDF)

Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes

The American journal of gastroenterology, 2006-06, Vol.101 (6), p.1288-1294

2006

Volltextzugriff (PDF)

Esomeprazole for the Management of Upper Gastrointestinal Symptoms in Patients Who Require NSAIDs: A Review of the NASA and SPACE Double-Blind, Placebo-Controlled Studies

Clinical drug investigation, 2009-01, Vol.29 (10), p.677-687

2009

Volltextzugriff (PDF)

Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management: A Prospective Observational Study

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013-02, Vol.13 (1), p.27-35

2013

Volltextzugriff (PDF)

The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010-01, Vol.10 (5), p.281-288

2010

Volltextzugriff (PDF)

The re-bleeding ulcer

Ugeskrift for læger, 2008-06, Vol.170 (26-32), p.2358

Naesdal, Jørgen

2008

Volltextzugriff (PDF)

Impact of irritable bowel syndrome on patientsʼ lives: development and psychometric documentation of a disease-specific measure for use in clinical trials

European journal of gastroenterology & hepatology, 2005-04, Vol.17 (4), p.411-420

2005

Volltextzugriff (PDF)

Randomized, Double-Blind, Placebo-Controlled Trial of the 5-HT 1A Receptor Antagonist AZD7371 Tartrate Monohydrate (Robalzotan Tartrate Monohydrate) in Patients With Irritable Bowel Syndrome

The American journal of gastroenterology, 2008-10, Vol.103 (10), p.2562-2569

2008

Volltextzugriff (PDF)

Management of gastroduodenal ulcers and gastrointestinal symptoms associated with nonsteroidal anti-inflammatory drug therapy: A summary of four comparative trials with omeprazole, ranitidine, misoprostol, and placebo

Current therapeutic research, 2001, Vol.62 (12), p.835-850

2001

Volltextzugriff (PDF)

Upper Gastrointestinal Symptoms Experienced by Users of Low-Dose Aspirin (Acetylsalicylic Acid) [75–325 mg/day] for Primary and Secondary Coronary Artery Disease Prevention: Perspectives from Patient Focus Groups

The patient : patient-centered outcomes research, 2009-06, Vol.2 (2), p.85-93

2009

Volltextzugriff (PDF)

Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA

Pragmatic and observational research, 2012-01, Vol.3, p.57-67

2012

Volltextzugriff (PDF)

Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic Acid

The patient : patient-centered outcomes research, 2011-06, Vol.4 (2), p.103

2011

Volltextzugriff (PDF)

Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs

European journal of gastroenterology & hepatology, 2001-12, Vol.13 (12), p.1401-1406

2001

Volltextzugriff (PDF)

Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol

Scandinavian journal of rheumatology, 2001, Vol.30 (6), p.328-334

Yeomans, Ingalill Wilson, Göran Längström, Christopher Hawkey, Jörgen Naesdal, Anders Walan, Ingela Wiklund, Neville

2001

Volltextzugriff (PDF)

W1021 A Single Capsule Formulation of Esomeprazole 40 Mg and Acetylsalicylic Acid 325 Mg Compared with the Monotherapies Given Separately: A Single-Dose Bioequivalence Study in Healthy Subjects

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-636-A-637

2009

Volltextzugriff (PDF)

Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies

Arthritis research & therapy, 2007, Vol.9 (1), p.R17-R17

2007

Volltextzugriff (PDF)

T1050 Dyspeptic Symptoms and Sleep Disturbance: A Report from a Large Observational Study in Low-Dose Acetylsalicylic Acid Users

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-488-A-488

2009

Volltextzugriff (PDF)

Lack of drug-drug interaction between esomeprazole and rofecoxib in healthy subjects

Gastroenterology (New York, N.Y. 1943), 2003-04, Vol.124 (4), p.A541-A541

2003

Volltextzugriff (PDF)

Lack of drug-drug interaction between esomeprazole and naproxen in healthy subjects

Gastroenterology (New York, N.Y. 1943), 2003-04, Vol.124 (4), p.A541-A541

2003

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(35)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(19)
Female
(14)
Male
(14)
Middle Aged
(13)
Biological And Medical Sciences
(12)
Adult
(11)
Medical Sciences
(11)
Aged
(10)
Anti-Inflammatory Agents, Non-Steroidal - Adverse Effects
(8)
Pharmacology. Drug Treatments
(8)
Double-Blind Method
(7)
Gastroenterology & Hepatology
(7)
Pharmacology & Pharmacy
(7)
Gastrointestinal Diseases - Chemically Induced
(6)
Medicine
(6)
Medicine & Public Health
(6)
Quality Of Life
(6)
Aspirin - Administration & Dosage
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors

NSAID-associated adverse effects and acid control aids to prevent them : A review of current treatment options

Low-Dose Aspirin Therapy for Cardiovascular Prevention: Quantification and Consequences of Poor Compliance or Discontinuation

Randomized, Double-Blind, Placebo-Controlled Trial of the 5-HT1A Receptor Antagonist AZD7371 Tartrate Monohydrate (Robalzotan Tartrate Monohydrate) in Patients With Irritable Bowel Syndrome

Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs

Improvements with Esomeprazole in Patients with Upper Gastrointestinal Symptoms Taking Non-Steroidal Antiinflammatory Drugs, Including Selective COX-2 Inhibitors

Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic Acid: A Quantitative Study in Patients with Cardiovascular Risk

Abnormal Intestinal Permeability in Subgroups of Diarrhea-Predominant Irritable Bowel Syndromes

Esomeprazole for the Management of Upper Gastrointestinal Symptoms in Patients Who Require NSAIDs: A Review of the NASA and SPACE Double-Blind, Placebo-Controlled Studies

Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management: A Prospective Observational Study

The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk

The re-bleeding ulcer

Impact of irritable bowel syndrome on patientsʼ lives: development and psychometric documentation of a disease-specific measure for use in clinical trials

Randomized, Double-Blind, Placebo-Controlled Trial of the 5-HT 1A Receptor Antagonist AZD7371 Tartrate Monohydrate (Robalzotan Tartrate Monohydrate) in Patients With Irritable Bowel Syndrome

Management of gastroduodenal ulcers and gastrointestinal symptoms associated with nonsteroidal anti-inflammatory drug therapy: A summary of four comparative trials with omeprazole, ranitidine, misoprostol, and placebo

Upper Gastrointestinal Symptoms Experienced by Users of Low-Dose Aspirin (Acetylsalicylic Acid) [75–325 mg/day] for Primary and Secondary Coronary Artery Disease Prevention: Perspectives from Patient Focus Groups

Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA

Impact of Gastrointestinal Problems on Adherence to Low-Dose Acetylsalicylic Acid

Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs

Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol

W1021 A Single Capsule Formulation of Esomeprazole 40 Mg and Acetylsalicylic Acid 325 Mg Compared with the Monotherapies Given Separately: A Single-Dose Bioequivalence Study in Healthy Subjects

Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies

T1050 Dyspeptic Symptoms and Sleep Disturbance: A Report from a Large Observational Study in Low-Dose Acetylsalicylic Acid Users

Lack of drug-drug interaction between esomeprazole and rofecoxib in healthy subjects

Lack of drug-drug interaction between esomeprazole and naproxen in healthy subjects

Suchergebnisse filtern